Drug Profile
Tipifarnib - Kura Oncology
Alternative Names: NSC-702818; R-115777; ZarnestraLatest Information Update: 19 Oct 2023
Price :
$50
*
At a glance
- Originator Janssen L.P.; Janssen-Cilag; Johnson & Johnson
- Developer Emory University; H. Lee Moffitt Cancer Center and Research Institute; Janssen-Cilag; Johnson & Johnson; Kura Oncology; National Cancer Institute (USA); Samsung Medical Center; Spanish Lung Cancer Group; University of Texas M. D. Anderson Cancer Center
- Class Amines; Antineoplastics; Cardiovascular therapies; Chlorobenzenes; Imidazoles; Ketones; Quinolines; Small molecules
- Mechanism of Action Farnesyltranstransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Acute myeloid leukaemia; Pancreatic cancer
- Phase II Chronic myelomonocytic leukaemia; Myelodysplastic syndromes; Non-small cell lung cancer; Peripheral T-cell lymphoma; Squamous cell cancer; Thyroid cancer; Urogenital cancer
- Phase I/II Multiple myeloma
- Phase I Solid tumours
- Preclinical Hypertrophic cardiomyopathy; Renal cell carcinoma; Rhabdomyosarcoma
- No development reported Cutaneous T-cell lymphoma
- Discontinued Breast cancer; Glioblastoma
Most Recent Events
- 19 Oct 2023 Efficacy and adverse events data from the phase II trial in Squamous cell cancer released by Kura Oncology
- 17 Oct 2023 Efficacy and adverse events data from a phase II AIM-HN trial in Squamous cell cancer released by Dana Farber Cancer Institute
- 21 Sep 2023 Kura Oncology terminates a phase I trial in Solid tumours (Late-stage disease) in USA (PO) due to recruitment challenges (NCT04865159)